Zai Lab Limited Unsponsored ADR (ZLAB) shares ended the last trading session 11.1% higher at $22.60. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.4% gain over the past four weeks.The recent surge in Zai Lab's stock price is likely due to positive investor expectations surrounding the strong ongoing performance of its marketed drugs, Zejula (for ovarian cancer), Vyvgart (for generalized myasthenia gravis), and ...